Orthocell Ltd (OCC) - Total Liabilities

Latest as of June 2025: AU$20.67 Million AUD ≈ $14.62 Million USD

Based on the latest financial reports, Orthocell Ltd (OCC) has total liabilities worth AU$20.67 Million AUD (≈ $14.62 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Orthocell Ltd (OCC) cash flow conversion to assess how effectively this company generates cash.

Orthocell Ltd - Total Liabilities Trend (2010–2025)

This chart illustrates how Orthocell Ltd's total liabilities have evolved over time, based on quarterly financial data. Check OCC asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Orthocell Ltd Competitors by Total Liabilities

The table below lists competitors of Orthocell Ltd ranked by their total liabilities.

Company Country Total Liabilities
Daesung Energy
KO:117580
Korea ₩298.71 Billion
One Point One Solutions Limited
NSE:ONEPOINT
India Rs1.05 Billion
Evolution Petroleum Corporation Inc
NYSE MKT:EPM
USA $101.72 Million
Satellos Bioscience Inc.
TO:MSCL
Canada CA$3.50 Million
Atrem S.A.
WAR:ATR
Poland zł152.29 Million
Jinzhou Port Co Ltd A
SHG:600190
China CN¥9.91 Billion
Thor Medical ASA
OL:TRMED
Norway Nkr87.50 Million
Peoples Bancorp of North Carolina
NASDAQ:PEBK
USA $1.55 Billion

Liability Composition Analysis (2010–2025)

This chart breaks down Orthocell Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see OCC stock market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 4.97 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio 4.47 Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.42 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.59 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Orthocell Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Orthocell Ltd (2010–2025)

The table below shows the annual total liabilities of Orthocell Ltd from 2010 to 2025.

Year Total Liabilities Change
2025-06-30 AU$20.67 Million
≈ $14.62 Million
-6.40%
2024-06-30 AU$22.08 Million
≈ $15.62 Million
-5.86%
2023-06-30 AU$23.46 Million
≈ $16.60 Million
-16.20%
2022-06-30 AU$27.99 Million
≈ $19.81 Million
+1039.68%
2021-06-30 AU$2.46 Million
≈ $1.74 Million
+8.34%
2020-06-30 AU$2.27 Million
≈ $1.60 Million
-21.10%
2019-06-30 AU$2.87 Million
≈ $2.03 Million
+0.54%
2018-06-30 AU$2.86 Million
≈ $2.02 Million
+16.81%
2017-06-30 AU$2.45 Million
≈ $1.73 Million
+9.77%
2016-06-30 AU$2.23 Million
≈ $1.58 Million
+3.54%
2015-06-30 AU$2.15 Million
≈ $1.52 Million
-57.48%
2014-06-30 AU$5.06 Million
≈ $3.58 Million
+636.52%
2013-06-30 AU$687.24K
≈ $486.27K
+100.36%
2011-06-30 AU$343.00K
≈ $242.69K
+67.32%
2010-06-30 AU$205.00K
≈ $145.05K
--

About Orthocell Ltd

AU:OCC Australia Biotechnology
Market Cap
$164.13 Million
AU$231.97 Million AUD
Market Cap Rank
#17278 Global
#507 in Australia
Share Price
AU$0.86
Change (1 day)
-2.29%
52-Week Range
AU$0.72 - AU$1.53
All Time High
AU$1.75
About

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally. It offers Ortho Autologous Chondrocyte Implantation, a cartilage cell therapy for treatment of articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membr… Read more